Advancing lung cancer detection through innovative biomarker technology. Dedicated to saving lives with early diagnosis and better outcomes.
- Tweets296
- Following59
- Followers101
- Likes46
ALT Cizzle Bio graphic for Dallas–Fort Worth healthcare providers titled “From first concern to the next clinical decision.” Outlines four steps: risk and history, imaging and assessment, additional biomarker information, and the next clinical decision. Shows lung imaging, a sample tube and a clinician reviewing patient information. Includes a “Review the ordering guide” prompt.
ALT Cizzle Bio graphic titled “Supporting earlier lung cancer detection,” featuring illustrated lungs and a Texas map with connected clinician icons. States that the CIZ1B test is commercially available to Dallas–Fort Worth clinicians as an additional biomarker tool within comprehensive clinical assessment. Includes a “Review clinical resources” prompt.
ALT Cizzle Bio graphic titled “Questions to ask about lung health,” a conversation guide for San Antonio patients to save for their next appointment. Shows a healthcare provider speaking with an older patient, alongside lung imaging and blood-test illustrations.
ALT Cizzle Bio graphic asking, “What factors affect my lung cancer risk?” Lists age, smoking history, family history, and environmental or workplace exposures. Encourages sharing medical history, symptoms and prior imaging with a provider for an individual assessment.
ALT Cizzle Bio graphic asking, “Should I undergo LDCT?” Explains that low-dose CT is an established imaging option for eligible people at increased risk. A provider can review current criteria, age and smoking history to determine whether it is appropriate.
ALT Cizzle Bio graphic asking, “Could biomarker testing provide additional information?” Explains that CIZ1B blood testing may add a data point to clinical assessment but does not replace LDCT screening, imaging, biopsy, specialist evaluation or clinical judgment. Advises asking a provider whether it may be appropriate.
ALT Cizzle Bio graphic for San Antonio healthcare providers highlighting CIZ1B test clinical resources and ordering setup, including clinical information, patient considerations, specimen guidance and onboarding steps. Shows a clinician speaking with a patient above the San Antonio skyline.
ALT Cizzle Bio graphic showing a clinician speaking with a patient above the San Antonio skyline. Encourages San Antonio patients to ask their healthcare provider about lung cancer risk, eligibility and whether additional assessment may be appropriate. Includes a “Learn about CIZ1B” prompt.
ALT Cizzle Bio graphic outlining CIZ1B test ordering setup for Dallas–Fort Worth providers: submit practice and provider information; receive onboarding and portal guidance; review ordering, specimen, shipping and results workflows; then complete onboarding and begin ordering when appropriate. Includes a “Begin ordering setup” prompt.
ALT Cizzle Bio graphic for Dallas–Fort Worth clinicians showing a clinician reviewing lung images and a gloved hand holding a blood sample. Text: “LDCT + the CIZ1B test. Different information. One comprehensive clinical assessment.”
ALT Cizzle Bio graphic explaining that low-dose CT (LDCT) produces detailed lung images and may identify nodules or other findings requiring clinical interpretation, illustrated with a clinician reviewing lung images.
ALT Cizzle Bio graphic showing a blood sample and a clinician reviewing lung images. Text explains that the CIZ1B test measures biomarker information from a blood sample for a licensed provider to consider.
ALT Cizzle Bio graphic titled “Different tools. Different information.” Text states that the CIZ1B test complements—not replaces—LDCT, imaging, biopsy, specialist evaluation and clinical judgment. Includes a “Read the article” prompt.
ALT Cizzle Bio graphic for Dallas–Fort Worth healthcare providers summarizing 2026 peer-reviewed evidence for the CIZ1B Biomarker Blood Test for Lung Cancer, including 94% sensitivity and 97% negative predictive value in the early-stage cohort.
ALT Cizzle Bio news graphic announcing its GenomeWeb feature about CIZ1B, a blood-based biomarker test for early-stage lung cancer detection.
ALT Cizzle Bio clinical-use graphic showing lungs and a blood sample with the question: A lung nodule is found—what information helps guide the next clinical decision?
ALT Cizzle Bio graphic explaining that a finding is not a diagnosis and should be assessed using patient history, risk factors, imaging, and specialist evaluation.
ALT Cizzle Bio graphic explaining that CIZ1B biomarker information may add clinical value within a comprehensive lung cancer assessment and does not replace imaging, biopsy, or clinical judgment.
ALT World Lung Day graphic from Cizzle Bio featuring an illustrated pair of lungs and a woman outdoors with her eyes closed, taking a deep breath. Text reads, “Your lung health matters. Know your risk. Start the conversation.” Footer reads, “@cizzlebio” and “Detect Early. Save Lives.”
ALT Illustration of lungs with branches and leaves, resembling trees. Clouds and birds are depicted inside the lungs. Text reads: "National Lung Cancer Screening Day." The background is blue.
ALT Illustration of lungs with branches and leaves, resembling trees. Clouds and birds are depicted inside the lungs. Text reads: "National Lung Cancer Screening Day." The background is blue.
ALT Puerto Rico-themed event graphic announcing the Prevent Cancer Foundation’s 2026 Annual Gala tonight at the National Building Museum in Washington, D.C., with support from Cizzle Bio.